A citation-based method for searching scientific literature

Robert J Motzer, Bernard Escudier, David F McDermott, Saby George, Hans J Hammers, Sandhya Srinivas, Scott S Tykodi, Jeffrey A Sosman, Giuseppe Procopio, Elizabeth R Plimack, Daniel Castellano, Toni K Choueiri, Howard Gurney, Frede Donskov, Petri Bono, John Wagstaff, Thomas C Gauler, Takeshi Ueda, Yoshihiko Tomita, Fabio A Schutz, Christian Kollmannsberger, James Larkin, Alain Ravaud, Jason S Simon, Li-An Xu, Ian M Waxman, Padmanee Sharma. N Engl J Med 2015
Times Cited: 3312



Marie Auvray, Edouard Auclin, Philippe Barthelemy, Petri Bono, Pirkko Kellokumpu-Lehtinen, Marine Gross-Goupil, Guillermo De Velasco, Thomas Powles, Guillaume Mouillet, Yann-Alexandre Vano, Gwenaëlle Gravis, Loïc Mourey, Franck Priou, Frédéric Rolland, Bernard Escudier, Laurence Albiges. Eur J Cancer 2019
Times Cited: 56




List of shared articles



Times cited

Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era.
Joaquim Bellmunt, Emilio Esteban, Xabier García Del Muro, Juan Manuel Sepúlveda, Pablo Maroto, Enrique Gallardo, Aranzazu González Del Alba, Olatz Etxaniz, Marta Guix, Jose Luis González Larriba,[...]. Eur Urol Oncol 2021
2

Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors.
Jeffrey Graham, Amishi Y Shah, J Connor Wells, Rana R McKay, Ulka Vaishampayan, Aaron Hansen, Frede Donskov, Georg A Bjarnason, Benoit Beuselinck, Guillermo De Velasco,[...]. Eur Urol Oncol 2021
11

Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study).
Yoshihiko Tomita, Go Kimura, Satoshi Fukasawa, Kazuyuki Numakura, Yutaka Sugiyama, Kazutoshi Yamana, Sei Naito, Koki Kabu, Yohei Tajima, Mototsugu Oya. Jpn J Clin Oncol 2021
1

A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
Ji Haeng Heo, Chanhyun Park, Somraj Ghosh, Sun-Kyeong Park, Marko Zivkovic, Karen L Rascati. J Clin Pharm Ther 2021
2

Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7).
Daniele Santini, Marco Stellato, Ugo De Giorgi, Francesco Pantano, Delia De Lisi, Chiara Casadei, Marco Maruzzo, Davide Bimbatti, Emanuele Naglieri, Sebastiano Buti,[...]. Am J Clin Oncol 2021
4